These are the stocks posting the largest moves in premarket trading

December 23, 2024 | 08:55am

Stocks making the biggest moves premarket: Novo Nordisk, Honda, Xerox, Tesla and more

These are the stocks posting the largest moves in premarket trading

Check out the companies making headlines in premarket trading. Novo Nordisk — The stock jumped about 5%, rebounding from the nearly 18% losses seen in the previous session. On Friday, the Danish pharmaceutical giant's experimental weight loss drug, CagriSema, reported late-stage trial results that missed expectations . Honda – U.S.-listed shares surged 15% after the company officially began merger talks with fellow Japanese automaker Nissan. The automakers plan to conclude discussions in June 2025. Xerox — The document services provider added nearly 7% after announcing its acquisition of printer maker Lexmark. The deal is worth $1.5 billion. Occidental Petroleum , Sirius XM , VeriSign — The stocks continued to rise in Monday's premarket after Warren Buffett disclosed last week that his Berkshire Hathaway conglomerate added to its stake in each name. Occidental and Sirius XM each climbed more than 2%, while VeriSign advanced 1.8%. Tesla — The electric vehicle maker bounced 3% before the bell, regaining some ground after last week's decline. Tesla slid 3.5% last week, which marked its worst weekly performance since before the U.S. presidential election. Despegar.com — Shares soared 32% after Prosus entered into a definitive agreement to buy the Argentina-based online travel platform for $19.50 per share. Prosus will pay $1.7 billion as part of the deal, which is expected to close in the second quarter of 2025. Traws Pharma — Shares of the clinical-stage virology company skyrocketed more than 76% after it announced progress in the development of its treatment for H5N1 bird flu. The company said tivoxavir marboxil showed safety and tolerability in the phase 1 trial, and it will begin a phase 2 study early next year. The news comes as the threat of bird flu is expected to rise. Immunocore — The biotech stock rose more than 5% on word that the first patient has been dosed with its experimental immunotherapy treatment, IMC-0115C. — CNBC's Sean Conlon and Christina Cheddar Berk contributed reporting

This story originally appeared on: CNBC - Author:Alex Harring